Methods and compositions for treatment of epileptic disorders
Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.
1. A method of treating CDKL5 deficiency disorder comprising administering to a patient in need thereof a pharmaceutical composition comprising ganaxolone or a pharmaceutically acceptable salt thereof wherein the patient is administered up to 1,800 mg of ganaxolone per day.
2. The method of claim 1 , wherein the patient is administered ganaxolone twice daily.
3. The method of claim 1 , wherein the pharmaceutical composition is an oral capsule.
4. The method of claim 1 , wherein the pharmaceutical composition is an oral suspension.
5. The method of claim 1 , wherein the pharmaceutical composition comprises 200 mg ganaxolone.
6. The method of claim 1 , wherein the pharmaceutical composition comprises 400 mg ganaxolone.
7. The method of claim 1 , wherein the pharmaceutical composition comprises 450 mg ganaxolone.
8. The method of claim 1 , wherein the pharmaceutical composition comprises 600 mg ganaxolone.
9. The method of claim 1 , wherein the pharmaceutical composition comprises 900 mg ganaxolone.
10. The method of claim 1 , wherein the pharmaceutical composition comprises 1800 mg ganaxolone.
11. The method of claim 1 , wherein the patient is administered oral capsules comprising 200-600 mg ganaxolone twice daily.
12. The method of claim 1 , wherein the composition provides reduction in the frequency of seizures.
13. The method of claim 1 , wherein the composition provides reduction in the frequency of seizures, the severity of seizures, or a combination thereof.